Oslo, Norway, 27 April 2026: Photocure ASA today announces the publication of
the Annual Report and integrated ESG report for 2025.
The Board of Directors of Photocure ASA has approved the annual accounts and
remuneration report for 2025. The financial statements and annual report for the
financial year 2025 are together with the ESG report and auditor's report
attached to this notice. The ESEF file and remuneration report for 2025 are also
attached.
The documents are enclosed and also made available at the company's website
under https://photocure.com/investors-hub/investors-events-and-presentations.
For further information, please contact:
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
About Photocure ASA
The Bladder Cancer Company delivers transformative solutions to improve the
lives of bladder cancer patients. Our unique technology, making cancer cells
glow bright pink, has led to better health outcomes for patients worldwide.
Photocure is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (OSE: PHO). For more information, please visit us at www.photocure.com
and www.cysview.com.
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA. This information is subject to the disclosure
requirements pursuant to sections 5-12 of the Norwegian Securities Trading Act.